Современный взгляд на проблему преэклампсии: аргументы и факты


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В данной статье приведены современные данные мировой и отечественной литературы в отношении одного из самых тяжелых осложнений беременности - преэклампсии. Представлены основные концепции патогенеза, а также обобщенные данные Кохрановских систематических обзоров последних лет, рекомендации американского общества акушеров и гинекологов (ACOG - American College of Obstetricians and Gynecologists, 2002), канадского общество акушеров и гинекологов (Society of Obstetricians and Gynaecologists of Canada, 2008), европейского общества по гипертензии и европейского общества кардиологов (European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2003; 2007), общества акушеров Австралии и Новой Зеландии (Society of Obstetric medicine of Australia and New Zealand, 2008) по терминологии, классификации, особенностям лечения и профилактики, выбору тактики ведения и родоразрешения пациенток с преэклампсией.

Полный текст

Доступ закрыт

Об авторах

Ираида Степановна Сидорова

ГБОУ Первый Московский государственный медицинский университет им. И.М. Сеченова

доктор медицинских наук, профессор, член-корреспондент РАМН, заслуженный деятель науки РФ 119991, Москва, ул. Трубецкая, д. 8, стр. 2

Наталья Александровна Никитина

ГБОУ Первый Московский государственный медицинский университет им. И.М. Сеченова

Email: natnikitina@list.ru
кандидат медицинских наук, доцент кафедры акушерства и гинекологии №1 119991, Москва, ул. Трубецкая, д. 8, стр. 2

Список литературы

  1. Jim B., Sharma S., Kebede T., Acharya A. Hypertension in pregnancy: a comprehensive update. Cardiol. Rev. 2010; 18(4): 178-89.
  2. Karthikeyan V.J., Lip G.Y. Endothelial damage/dysfunction and hypertension in pregnancy. Front. Biosci. (Elite Ed). 2011; 3: 1100-8.
  3. Duley L. The global impact of pre-eclampsia and eclampsia. Semin. Perinatol. 2009; 33(3): 130-7.
  4. Fabry I.G., Richart T., Chengz X., Van Bortel L.M., Staessen J.A. Diagnosis and treatment of hypertensive disorders during pregnancy. Acta Clin. Belg. 2010; 65(4): 229-36.
  5. Hutcheon J.A., Lisonkova S., Joseph K.S. Epidemiology of preeclampsia and the other hypertensive disorders of pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 2011; 25(4): 391-403.
  6. Khan K.S., Wojdyla D., Say L., Gulmezoglu A.M., Van Look P.F. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367(9516): 1066-74.
  7. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Preeclampsia. Lancet. 2010; 376(9741): 631-44.
  8. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva; 2011.
  9. Макаров О.В., Ткачева О.Н., Волкова Е.В. Преэклампсия и хроническая артериальная гипертензия. Клинические аспекты. М.: ГЭОТАР-Медиа; 2010. 136 с.
  10. Милованов А.П., ред. Анализ причин материнской смертности: Руководство для врачей. М.: МДВ; 2008. 228 с.
  11. Ghulmiyah L., Sibai B. Maternal mortality from preeclampsia/ eclampsia. Semin. Perinatol. 2012; 36(1): 56-9.
  12. Hypertension in Pregnancy: The management of hypertensive disorders during pregnancy. NICE Clinical Guidelines, No. 107. National Collaborating Centre for Women’s and Children’s Health (UK). London: RCOG Press; August 2010.
  13. Yucesoy G., Ozkan S., Bodur H., Tan T., Caliskan E., Vural B., Corakci A. Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center. Arch. Gynecol. Obstet. 2005; 273(1): 43-9.
  14. Schroeder B.M.; American College of Obstetricians and Gynecologists. ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. American College of Obstetricians and Gynecologists. Am. Fam. Physician. 2002; 66(2): 330-1.
  15. Добряков А.В. Патологоанатомическая диагностика различных видов гестоза при современном их лечении: Автореф. дис.. канд. мед. наук. М.; 2005. 24 с.
  16. Agostinis C., Bossi F., Masat E., Radillo O., Tonon M., De Seta F. et al. MBL interferes with endovascular trophoblast invasion in pre-eclampsia. Clin. Dev. Immunol. 2012; 2012: 484321.
  17. Shamshirsaz A.A., Paidas M., Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation. J. Pregnancy. 2012; 2012: 374047.
  18. Fisher S.J. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod. Biol. Endocrinol. 2004; 2: 53.
  19. Ogge G., Chaiworapongsa T., Romero R., Hussein Y., Kusanovic J.P., Yeo L. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J. Perinat. Med. 2011; 39(6): 641-52.
  20. Ong S.S., Baker P.N., Mayhew T.M., Dunn W.R. Remodeling of myometrial radial arteries in preeclampsia. Am. J. Obstet. Gynecol. 2005; 192(2): 572-9.
  21. Rusterholz C., Gupta A.K., Huppertz B., Holzgreve W., Hahn S. Soluble factors released by placental villous tissue: Interleukin-1 is a potential mediator of endothelial dysfunction. Am. J. Obstet. Gynecol 2005; 192(2): 618-24.
  22. Arici D.S., Guvenal T., Elagoz S., Qetin M., Toyaksi M. Evaluation of trophoblast invasion in placental bed biopsies of women with Normal and Severe Preeclamptic Pregnancies. Turk. Klin. J. Med. Res. 2000; 18: 64-8.
  23. Габелова К.А., Арутюнян А.В., Зубжицкая Л.Б., Опарина Т.И., Парусов В.Н. Фиксированные иммунные комплексы и NO-синтетазная активность плаценты при гестозе. Вестник Российской ассоциации акушеров-гинекологов. 2000; 1: 22-4.
  24. Зубжицкая Л.Б., Кошелева Н.Г., Семенов В.В. Иммуноморфологическое состояние плаценты при акушерской патологии. СПб.: Нордмедиздат; 2005. 304 с.
  25. Redman C.W., Sargent I.L. Pre-eclampsia, the placenta and the maternal systemic inflammatory response: a review. Placenta. 2003; 24: 21-7.
  26. Lamarca B. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia. Minerva Ginecol. 2012; 64(4): 309-20.
  27. Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol. 2010 ; 62(2): 105-20.
  28. Lazdam M., Davis E.F., Lewandowski A.J., Worton S.A., Kenworthy Y., Kelly B., Leeson P. Prevention of vascular dysfunction after preeclampsia: a potential long-term outcome measure and an emerging goal for treatment. J. Pregnancy. 2012; 2012: 704146.
  29. Yinon Y., Kingdom J.C., Odutayo A., Moineddin R., Drewlo S., Lai V et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation. 2010; 122(18): 1846-53.
  30. Evans C.S., Gooch L., Flotta D., Lykins D., Powers R.W., Landsittel D. et al. Cardiovascular system during the postpartum state in women with a history of preeclampsia. Hypertension. 2011; 58(1): 57-62.
  31. Kvehaugen A.S., Dechend R., Ramstad H.B., Troisi R., Fugelseth D., Staff A.C. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension. 2011; 58(1): 63-9.
  32. Freeman D.J., McManus F., Brown E.A., Cherry L., Norrie J., Ramsay J.E. et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension. 2004; 44(5): 708-14.
  33. Uzan J., Carbonnel M., Piconne O., Asmar R., Ayoub J.-M. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc. Health Risk Manag. 2011; 7: 467-74.
  34. Magee L.A., Yong P.J., Espinosa V., Cote A.M., Chen I., von Dadelszen P. Expectant management of severe preeclampsia remote from term: a structured systematic review. Hypertens. Pregnancy. 2009; 28(3): 312-47.
  35. Pettit F.B., Brown M.A. The management of pre-eclampsia: what we think we know. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 160(1): 6-Duley L., Gulmezoglu A.M., Henderson-Smart D.J., Chou D. Magnesium sulfate and other anticonvulsants for women with preeclampsia. Cochrane Database Syst. Rev. 2010; (11): CD000025.
  36. Eiland E., Nzerue C., Faulkner M. Preeclampsia 2012. J. Pregnancy. 2012; 2012: 586578.
  37. McDonald S.D., Lutsiv O., Dzaja N., Duley L. A systematic review of maternal and infant outcomes following magnesium sulfate for pre-eclampsia/eclampsia in real-world use. Int. J. Gynaecol. Obstet. 2012; 118(2): 90-6.
  38. Dennis A.T. Management of pre-eclampsia: issues for anaesthetists. Anaesthesia. 2012; 67(9): 1009-20.
  39. Abbassi-Ghanavati M., Alexander J.M., Mclntire D.D., Savani R.C., Leveno K.J. Neonatal effects of magnesium sulfate given to the mother. Am. J. Perinatol. 2012; 29(10): 795-800.
  40. Doyle L.W., Crowther C.A., Middleton P., Marret S., Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst. Rev. 2009; (1): CD004661.
  41. Magee L., Sawchuck D., Synnes A., von Dadelszen P. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. J. Obstet. Gynaecol. Can. 2011; 33(5): 516-29.
  42. Eshkoli T., Holcberg G., Bronfenmacher B., Amash A., Huleihel M., Erez O. Perfusion with magnesium sulfate increases sFlt-1 secretion only in the fetal side of placenta of women with preeclampsia. J. Matern. Fetal Neonatal Med. 2013; 26(2): 116-22.
  43. Шифман Е.М. Преэклампсия. Эклампсия. HELLP-синдром. Петрозаводск: ИнтелТек; 2002. 430 с.
  44. Boldt J., Heesen M., Padberg W., Martin K., Hempelmann G. The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients. Anaesthesia. 1996; 51(6): 529-35.
  45. Blasco V., Leone M., Antonini F., Geissler A., Albanese J., Martin C. Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br. J. Anaesth. 2008; 100(4): 504-8.
  46. De Vries J.I., van Pampus M.G., Hague W.M., Bezemer P.D., Joosten J.H.; FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onsetpre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J. Thromb. Haemost. 2012; 10(1): 64-72.
  47. Drewlo S., Levytska K., Sobel M., Baczyk D., Lye S.J., Kingdom J.C. Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling. J. Thromb. Haemost. 2011; 9(12): 2486-97.
  48. Gris J.C., Chauleur C., Molinari N., Mares P., Fabbro-Peray P., Quere I. et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb. Haemost. 2011; 106(6): 1053-61.
  49. Kingdom J.C., Drewlo S. Is heparin a placental anticoagulant in high-risk pregnancies? Blood. 2011; 118(18): 4780-8.
  50. Kupferminc M., Rimon E., Many A., Maslovitz S., Lessing J.B., Gamzu R. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul. Fibrinolysis. 2011; 22(2): 123-6.
  51. Martinelli I., Ruggenenti P., Cetin I., Pardi G., Perna A., Vergani P. et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012; 119(14): 3269-75.
  52. Foidart J.M., Schaaps J.P., ChantraineF., Munaut C., Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PIGF, and sEndoglin) in preeclampsia - a step forward but not the definitive answer. J. Reprod. Immunol. 2009; 82(2): 106-11.
  53. Rosenberg V.A., Buhimschi I.A., Lockwood C.J., Paidas M.J., Dulay A.T., Ramma W. et al. Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy. Circulation. 2011; 124(23): 2543-53.
  54. Zhang Y., Zhong M., Liu F. Low molecular weight heparin inhibits cell apoptosis in the placenta of rats with preeclampsia-like symptoms. Nan Fang Yi Ke Da Xue Xue Bao. 2012; 32(6): 862-6.
  55. Sobel M.L., Kingdom J., Drewlo S. Angiogenic response of placental villi to heparin. Obstet. Gynecol. 2011; 117(6): 1375-83.
  56. Mustafa R., Ahmed S., Gupta A., Venuto R.C. A comprehensive review of hypertension in pregnancy. J. Pregnancy. 2012; 2012: 105918.
  57. Knight M., Duley L., Henderson-Smart D.J., King J.F. WITHDRAWN: Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst. Rev. 2007; (2): CD000492.
  58. Villa P., Kajantie E., Raikkonen K., Pesonen A.K., Hamalainen E., Vainio M. et al.; PREDO Study group. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. Br. J. Obstet. Gynaecol. 2013; 120(1): 64-74.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах